A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intravenously in Patients With Advanced High-Grade Osteosarcoma

Vall d'Hebron Institute of Oncology1 site in 1 country10 target enrollmentDecember 27, 2024

ConditionsOsteosarcoma Osteosarcoma in Children

InterventionsOMO-103

DrugsOMO-103

Overview

Phase: Phase 2
Intervention: OMO-103
Conditions: Osteosarcoma
Sponsor: Vall d'Hebron Institute of Oncology
Enrollment: 10
Locations: 1
Primary Endpoint: Preliminary anti-tumour activity of OMO-103 monotherapy in patients with high-grade osteosarcoma
Status: Recruiting
Last Updated: last year

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This is an open-label, unicentric, single-arm Phase 2 pilot study to serve as a proof-of-concept of OMO-103 safety and activity in patients with advanced high-grade osteosarcoma.

Patients will be treated at the RP2D (6.5 mg/kg as a weekly IV infusion) of OMO-103 to estimate anti-tumour activity and further characterise the safety, tolerability, PK, and PD of OMO-103 in advanced high-grade osteosarcoma patients. Ten (10) evaluable patients will be enrolled. At least 30% of patients will be <18 years old. The first three patients 12-15 years of age will undergo additional safety monitoring.

Patients will be treated until progression by RECIST v1.1 or intolerable toxicity.

Registry

clinicaltrials.gov

Start Date

December 27, 2024

End Date

December 2026

Last Updated

last year

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Vall d'Hebron Institute of Oncology

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Provision of signed and dated informed consent form.
•Age ≥12 years at time of informed consent.
•Histologically proven, advanced high-grade osteosarcoma not suitable for local treatments with curative intent
•Confirmed disease progression by radiological report to at least one line of standard chemotherapy containing cisplatin and anthracycline, and no more than 2 previous lines.
•Measurable disease as per RECIST v1.1 criteria and documented by CT/MRI (Appendix 1 - RECIST Response Criteria). NOTE: Lesions to be used as measurable disease for the purpose of response assessment must either:
•not reside in a field that has been subjected to prior radiotherapy, or
•have demonstrated clear evidence of radiographic progression since the completion of prior radiotherapy and prior to study enrolment.
•Provision of a newly obtained tumour biopsy (either from the primary tumour or from metastases) during screening and on-treatment from all patients \>16 years of age. Notes:
•The identified lesion to be biopsied should not have been previously irradiated and should not be the only lesion being used as a measurable-disease target lesion for objective response assessment. Patients must have tumour lesions that can be accessible for biopsy with acceptable clinical risk in the judgement of the Investigator.
•In case a patient has had a tumour biopsy in the previous 6 months and a paraffin block is available, a new biopsy does not need to be done at Screening (if they have received no treatment after biopsy).

Exclusion Criteria

•Treatment with systemic anti-cancer therapy within three weeks prior to study drug administration for chemotherapy and 5 half-lives for targeted therapies.
•Radiation therapy within four weeks prior to study entry. Localised palliative radiotherapy to nontarget lesions is allowed
•Low-grade osteosarcoma, parosteal, or periosteal osteosarcoma.
•Prior history of other malignancies other than osteosarcoma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix) unless the patient has been free of the disease for at least 2 years.
•Non-malignant systemic disease including cerebrovascular accident, unstable angina pectoris, unstable atrial fibrillation, unstable cardiac arrhythmia, myocardial infarction in the last six months, New York Heart Association (NYHA) Class III or IV heart failure (Appendix 5 - New York Heart Association Criteria).
•Patients with active uncontrolled infection or known to be serologically positive for human immunodeficiency virus (HIV), hepatitis B (except after vaccination) or hepatitis C infection. Investigators may test as per their discretion.
•Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study.
•Patients with symptomatic or unstable central nervous system primary tumour or metastases and/or sarcomatous meningitis
•Live vaccine in the last four weeks.
•Current participation in another interventional therapeutic trial.

Arms & Interventions

OMO-103

OMO-103 administered at the recommended phase 2 dose (6.5 mg/kg as a weekly intravenous infusion in 28-day cycles)

Intervention: OMO-103

Outcomes

Primary Outcomes

Preliminary anti-tumour activity of OMO-103 monotherapy in patients with high-grade osteosarcoma

Time Frame: 16 weeks from start of treatment

Progression-free survival rate at 16 weeks (16-week PFS)

Secondary Outcomes

Further evaluate the anti-tumour activity of OMO-103 monotherapy in patients with high-grade osteosarcoma.(Until patient request or death whichever occurs first, assessed up to 24 months)
Safety and tolerability profile of OMO-103 monotherapy in patients with high-grade osteosarcoma.(Unrtil end of treatment assessed up to 24 months)
Assess the benefit/risk ratio associated with OMO-103(Until progression assessed up to 24 months)
To characterise the pharmacokinetics (PK) of OMO-103 monotherapy in patients with high-grade osteosarcoma (12-15 years of age).(During the first cycle of treatment (4 weeks))
Evaluate quality of life (QoL) in patients with high-grade osteosarcoma(Unitl end of treatment assessed up to 24 months)